Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections

News provided by

Debiopharm Group

23 Apr, 2015, 06:30 GMT

LAUSANNE, Switzerland, April 23, 2015 /PRNewswire/ --

One year after the initiation of Phase I, Debiopharm announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID 

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.

This study is designed as a dose-response study to evaluate the efficacy of Debio 1450 in both intravenous (IV) and oral formulations versus intravenous vancomycin switched to oral linezolid in the treatment of ABSSSI. Safety and tolerability of both the IV and oral formulations of Debio 1450 will be evaluated by conventional endpoints.

Moreover, Debiopharm will present data regarding Debio 1450 PK/PD at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held from 25 - 28 April 2015 in Copenhagen.

During ECCMID, Debiopharm will also take part in the Pipeline Corner project, a unique event organized on behalf of the European Society of Clinical Microbiology and Infectious Diseases, allowing companies to present their innovative anti-infective projects and meet stakeholders in this field. Please visit us at Pipeline Corner: Hall K - L

"Only one year after the enrollment of the administration of the first patient in Phase I, we are happy to announce the initiation of clinical PhII in ABSSSI", said Dr Jean-Maurice Dumont, Vice President, Medical Affairs, Debiopharm International. "It emphasizes our commitment to develop highly valuable targeted antibiotics in order to alleviate problems of acquired resistance linked to broad-spectrum antibiotic usage".

Details of Debiopharm's presentations at ECCMID 

             Poster             Oral Presentation               Event
    Date     Sat, Apr 25        Mon, Apr 27                     Mon, Apr 27
             Session EV27       Session OS22                    1:00 - 2:00 pm
                                New studies in antibacterial
                                drug PK/PD
    Title    Methods for        Translational                   Debiopharm
             antibacterial      pharmacokinetic/pharmacodynamic "elevator pitch"
             susceptibility     modeling of oral and            with a focus on
             testing            intravenous Debio 1450, a new   antibacterials
             Debio 1452 MIC     staphylococcal specific
             quality control    antibiotic
             range with
             Staphylococcus
             aureus ATCC 29213
             using a
             multi-laboratory
             study design
             (EV0763)
    Speaker                     Valérie Nicolas                 Fabien Sebille
                                                                Pipeline Corner
    Location ePoster Area       Hall F                          Hall K-L

About Debio 1450 

Debio 1450 is a prodrug of Debio 1452, it is a highly potent anti-infective agent that is specifically active against all Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA). Oral and IV Debio 1450 formulations are being developed for clinical use in several serious infections. Moreover Debio 1452 had a successful phase IIa with 103 patients in ABSSSI.

About Debiopharm International SA 

Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
christelle.tur@debiopharm.com
Tel: +41(0)21-321-01-11

Additional Media Contacts
In London
Maitland
Martin Barrows
mbarrow@maitland.co.uk
Tel: +44(0)20-7395-0444

In New York
Russo Partners, LLC
Marissa Goberdhan
Account Executive
marissa.goberdhan@russopartnersllc.com
Tel: +1-212-845-4253